Consalvo Petti

TL;DR: Ciardiello et al. as discussed by the authors found that HER2 amplification was a predictor of resistance to anti-epidermal growth factor receptor (EGFR) antibodies and response to combination therapies against HER2 in this tumor setting.

TL;DR: Analysis of CRC expression data from patient-derived xenografts shows that the distinctive transcriptional and clinical features of the SSM subtype can be ascribed to its particularly abundant stromal component.

TL;DR: Five CRC intrinsic subtypes (CRIS) endowed with distinctive molecular, functional and phenotypic peculiarities successfully categorize independent sets of primary and metastatic CRCs, with limited overlap on existing transcriptional classes and unprecedented predictive and prognostic performances.

TL;DR: An analytical pipeline, microRNA master regulator analysis (MMRA), developed to search for microRNAs potentially driving CRC subtypes is described, showing that, by combining statistical tests, target prediction and network analysis, MMRA effectively identifies micro RNAs functionally associated to cancer subtypes.

TL;DR: These results provide the first mechanism of secondary resistance to WNT pathway inhibition, and a pipeline designed to suppress stroma‐derived signal finds that RSPO3 “outlier” expression in CRC samples highlights translocation and fusion transcript expression.